전이위암 환자에서 라무시루맙 화학 요법 후 발생한 급성 뇌경색
Acute Ischemic Stroke in a Patient with Metastatic Gastric Cancer after Ramucirumab Chemotherapy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Ramucirumab is a vascular endothelial growth factor (VEGF) receptor-2 inhibiting monoclonal antibody for the treatment of gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. Some VEGF inhibitors are known to increase the risk of ischemic stroke; however, their association with ramucirumab remains controversial. To the best of our knowledge, only two cases of ischemic stroke following ramucirumab treatment have been reported worldwide. We herein present the first case of acute cerebral infarction secondary to ramucirumab in Korea.
Abstract
Ramucirumab is a vascular endothelial growth factor (VEGF) receptor-2 inhibiting monoclonal antibody for the treatment of gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. Some VEGF inhibitors are known to increase the risk of ischemic stroke; however, their association with ramucirumab remains controversial. To the best of our knowledge, only two cases of ischemic stroke following ramucirumab treatment have been reported worldwide. We herein present the first case of acute cerebral infarction secondary to ramucirumab in Korea.
참고문헌 (10)
- Greig SL, "Ramucirumab : a review in advanced gastric cancer", BioDrugs, 29, pp.341~351 (2015)
- Zangari M, "Thrombotic events in patients with cancer receiving antiangiogenesis agents", J Clin Oncol, 27, pp.4865~4873 (2009)
- Totzeck M, "Cardiovascular adverse events in patients with cancer treated with bevacizumab : a meta-analysis of more than 20 000 patients", J Am Heart Assoc, 6, pp.e006278~ (2017)
- Arnold D, "Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab", Ann Oncol, 28, pp.2932~2942 (2017)
- Christiansen ME, "A case report of ischemic stroke in a patient with metastatic gastric cancer secondary to treatment with the vascular endothelial growth factor receptor-2 inhibitor ramucirumab", Case Rep Oncol, 9, pp.317~320 (2016)
- Chen GY, "Ischemic stroke in a patient with EGFR-mutated non-small-cell lung cancer after treatment with ramucirumab", Thorac Cancer, 13, pp.3412~3414 (2022)
- Fuchs CS, "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial", Lancet, 383, pp.31~39 (2014)
- Kamba T, "Mechanisms of adverse effects of anti-VEGF therapy for cancer", Br J Cancer, 96, pp.1788~1795 (2007)
- Matsumura C, "Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database", J Oncol Pharm Pract, 24, pp.22~27 (2018)
- Kim K, "Pro-coagulant and pro-thrombotic effects of paclitaxel mediated by red blood cells", Thromb Haemost, 118, pp.1765~1775 (2018)